文献速递肾小球疾病急性肾损伤遗传性与小管间质肾病

肾脏疾病中的补体系统:核心教程2026

Complement in Kidney Disease: Core Curriculum 2026.
PubMed 文献 · Am J Kidney Dis · 2026-09-11

补体级联是天然免疫的一部分,其不当或过度激活可驱动多种肾脏炎症。美国FDA已批准补体抑制药物用于治疗5种肾脏疾病:非典型溶血性尿毒症综合征、C3肾小球病、免疫复合物膜增生性肾小球肾炎、抗中性粒细胞胞质抗体相关性血管炎和IgA肾病。正在进行的临床试验在测试新的抗补体药物及更多肾脏适应症。

要点

  • FDA已批准补体抑制剂用于5种肾脏疾病,包括aHUS、C3G、IC-MPGN、ANCA相关血管炎和IgA肾病。
  • 补体激活可产生血浆、尿液和组织生物标志物,是临床评估炎症和自身免疫性肾病的重要部分。
  • 肾内科医生需熟悉现有抗补体药物和补体诊断方法,未来肾脏适应症可能扩大。

核心结论

  • 补体系统的不当或过度激活是多种肾脏炎症的驱动因素,补体抑制药物已成为部分肾脏疾病的获批治疗手段。
  • 肾内科医生应熟悉抗补体药物和补体诊断,以应对不断扩展的肾脏适应症。

研究设计与样本

  • 本文为核心教程(Core Curriculum),综述补体级联在肾脏疾病中的作用、已获批补体抑制药物及补体诊断。

主要发现

  • 美国FDA已批准补体抑制药物用于治疗5种肾脏疾病:非典型溶血性尿毒症综合征、C3肾小球病、免疫复合物膜增生性肾小球肾炎、抗中性粒细胞胞质抗体相关性血管炎和IgA肾病。
  • 正在进行的临床试验在测试新的抗补体药物和补体抑制剂的其他肾脏适应症。
  • 大多数免疫抑制药物不直接阻断补体激活。
  • 补体激活在肾脏疾病中产生血浆、尿液和组织生物标志物。

临床怎么用

  • 肾内科医生应熟悉现有抗补体药物及其获批的肾脏适应症。
  • 对炎症性和自身免疫性肾病患者,应将补体系统实验室评估纳入临床检查。
  • 关注补体抑制剂在肾脏疾病中不断扩展的适应症和正在进行的临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The complement cascade is part of the innate immune system, and it provides an important line of defense against infections. Inappropriate or excessive activation of this system, however, is also a driver of kidney inflammation in many diseases. Complement inhibitory drugs have now been approved by the US Food and Drug Administration for the treatment of 5 renal diseases: atypical hemolytic uremic syndrome, C3 glomerulopathy, immune-complex membranoproliferative glomerulonephritis, antineutrophil cytoplasmic antibody-associated vasculitis, and IgA nephropathy. Ongoing clinical trials are testing new anticomplement drugs and additional renal indications for complement inhibitors. Most immunosuppressive drugs do not directly block complement activation, and the use of complement inhibitors for renal indications is likely to expand in the coming years. Complement activation in renal diseases also generates plasma, urine, and tissue biomarkers, and laboratory evaluation of the complement system is an important part of the clinical work-up of patients with these inflammatory and autoimmune conditions. It is essential, therefore, that nephrologists are familiar with the available anticomplement drugs and with complement diagnostics.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Thurman JM, Poppelaars F. Complement in Kidney Disease: Core Curriculum 2026. Am J Kidney Dis. 2026. PMID: 42726032. doi:10.1053/j.ajkd.2026.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。